

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934

June 2017

Commission file number: 001-36288

Akari Therapeutics, Plc  
(Translation of registrant's name into English)

24 West 40<sup>th</sup> Street, 8<sup>th</sup> Floor  
New York, NY 10018  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): \_\_\_\_\_

---

## CONTENTS

On June 28, 2017, an Annual General Meeting of Shareholders of Akari Therapeutics, Plc. (the “Company”) was held. At the meeting, all proposals brought before the Company’s shareholders were approved in accordance with the majority required for each proposal, with the exception of proposal no. 10, which was not put to a vote at the meeting. Each of those proposals was described in the Company’s Notice of Annual General Meeting of Shareholders, dated May 15, 2017, and in its Proxy Statement, dated May 15, 2017, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on May 16, 2017.

The information contained in this report (including the exhibits hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form S-3, File No. 333-207443, Form S-8 (No. 333-198109 and 333-207444), Registration Statement on Form F-3 File No. 333-198107, and the Registration Statements on Post-Effective Amendments to Form F-1 on Form F-3 (333-185247, 333-187826 and 333-191880).

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Akari Therapeutics, Plc  
(Registrant)

By: /s/ Robert M. Shaw  
Name: Robert M. Shaw  
General Counsel & Secretary

Date: June 29, 2017

---